JPRN-jRCTs031220444进行中（未招募）2 期
An Extension study of trastuzumab and pertuzumab comination therapy for HER2 amplified advanced solid tumors
Ikeda Sadakatsu0 个研究点目标入组 3 人开始时间: 2022年11月11日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1) Patients enrolled in the Phase II study and continuing on study treatment at the time of obtaining consent for this study.
- •(2) Women of child-bearing potential and partners of child-bearing potentail must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for 28 weeks following completion of study therapy.
- •(3) Patients signed informed consent form.
排除标准
- •(1) Patients who participated in clinical studies other than the Phase II trials within 4 weeks prior to obtaining consent for this study.
- •(2) Patients who have a clinically significant medical condition that makes participation in this study inadvisable or makes compliance with the requirements of this study difficult.
- •(3) Any other patients who are regarded as inappropriate for inclusion in the study.
研究者
相似试验
招募中
2 期
A Phase II study of pertuzumab+trastuzumab+capecitabine in Patients with taxans and trastuzumab refractory for advanced or recurrent breast cancerHER2-positive metastatic breast cancerJPRN-UMIN000012030Saitama Breast Cancer Clinical Study Group30
已完成
2 期
A phase II trial of pertuzumab and trastuzumab in combination with capecitabine in patients with metastatic breast cancer who received prior trastuzumab combination chemotherapy.Breast cancerJPRN-UMIN000012208Kurume University Hospital24
已完成
不适用
Observational study of Pertuzumab,Trastuzumab and taxane combination therapy for patient with pretreated HER2-positive advanced or recurrent breast cancer.advanced or recurrent breast cancerJPRN-UMIN000013607Shonankamakura General Hospital50
已完成
不适用
Early monitoring of trastuzumab +/- pertuzumab therapy with 18F-choline PET/CT in patients with advanced disease breastcancer.NL-OMON39351Catharina-ziekenhuis23
暂停
不适用
Phase II trial of pertuzumab and trastuzumab in combination with S-1 for patients with HER2-positive metastatic breast cancerBreast cancerJPRN-UMIN000024477Kurume University School of Medicine32